Eli Lilly & Company recently acquired Disarm Therapeutics, a pre-clinical NAD-boosting company treating neuropathy and neurodegenerative diseases, for $135 million and a potential additional $1.2 billion in milestones. Disarm was founded by Atlas Venture; Jeff...
